表紙:TCR療法の世界市場(2022年~2035年):適応症別、標的抗原別、主要参入企業別、主要地域別:業界動向と世界の予測、2022年~2035年
市場調査レポート
商品コード
1182863

TCR療法の世界市場(2022年~2035年):適応症別、標的抗原別、主要参入企業別、主要地域別:業界動向と世界の予測、2022年~2035年

Global TCR Therapy Market, 2022-2035: Distribution by Target Indication, Target Antigen, Key Players and Key Geographies : Industry Trends and Global Forecasts, 2022-2035

出版日: | 発行: Roots Analysis | ページ情報: 英文 363 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
TCR療法の世界市場(2022年~2035年):適応症別、標的抗原別、主要参入企業別、主要地域別:業界動向と世界の予測、2022年~2035年
出版日: 2023年09月01日
発行: Roots Analysis
ページ情報: 英文 363 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のTCR療法市場について調査し、市場の概要とともに、適応症別、標的抗原別、主要参入企業別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 TCR療法:市場情勢

  • 章の概要
  • TCR療法:全体的な市場情勢
  • TCR療法:開発者の全体情勢

第5章 一般的な標的抗原分析

第6章 臨床試験分析

  • 章の概要
  • 範囲と調査手法
  • TCR療法:臨床試験の分析

第7章 主なオピニオンリーダー

  • 章の概要
  • 仮定と主なパラメータ
  • 調査手法
  • TCR療法:キーオピニオンリーダー

第8章 TCRベースの治療プロファイル

第9章 パートナーシップとコラボレーション

  • 章の概要
  • パートナーシップモデル
  • TCR療法:パートナーシップとコラボレーション

第10章 資金調達と投資分析

第11章 特許分析

第12章 ケーススタディ:細胞療法の製造

第13章 原価分析

第14章 市場予測と機会分析

  • 章の概要
  • 範囲と制限
  • 主な仮定と予測調査手法
  • 世界のTCR療法市場、2022年~2035年

第15章 プロモーション分析

第16章 企業プロファイル

  • 章の概要
  • Adaptimmune Therapeutics
  • Alaunos Therapeutics
  • Company Profiles
  • Bristol Myers Squibb
  • Cellular Biomedicine Group
  • Gilead Sciences
  • Cellular Biomedicine Group
  • GlaxoSmithKline
  • Immatics
  • Immunocore
  • Lion TCR
  • Takara Bio
  • Zelluna immunotherapy

第17章 結びの言葉

第18章 エグゼクティブインサイト

第19章 付録1:表形式のデータ

第20章 付録2:会社および組織のリスト

図表

LIST OF TABLES

  • Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
  • Table 3.2 FDA Approved Antibody-based Cancer Therapeutics
  • Table 3.3 Retroviral Vectors: Salient Features
  • Table 3.4 Lentiviral Vectors: Salient Features
  • Table 3.5 CAR-T Cell and TCR-based Therapies: Key Differences
  • Table 4.1 TCR-based Therapies: Clinical Pipeline
  • Table 4.2 TCR-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
  • Table 4.3 TCR-based Therapies: Preclinical Pipeline
  • Table 4.4 List of TCR-based Developers
  • Table 8.1 TCR-based Cell Therapies: List of Therapies Profiled
  • Table 8.2 Therapy Profile: Kimmtrak (Immunocore)
  • Table 8.3 Kimmtrak: Clinical Trial Information
  • Table 8.4 Kimmtrak: Clinical Trial Endpoints
  • Table 8.5 Kimmtrak: Clinical Trial Results
  • Table 8.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
  • Table 8.7 GSK3377794: Clinical Trial Information
  • Table 8.8 GSK3377794: Clinical Trial Endpoints
  • Table 8.9 GSK3377794: Clinical Trial Results
  • Table 8.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
  • Table 8.11 ADP-A2M4: Clinical Trial Information
  • Table 8.12 ADP-A2M4: Clinical Trial Endpoints
  • Table 8.13 ADP-A2M4: Clinical Trial Results
  • Table 8.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
  • Table 8.15 JTCR016: Clinical Trial Information
  • Table 8.16 JTCR016: Clinical Trial Endpoints
  • Table 8.17 Therapy Profile: TBI-1301 (Takara Bio)
  • Table 8.18 TBI-1301: Clinical Trial Information
  • Table 8.19 TBI-1301: Clinical Trial Endpoints
  • Table 8.20 TBI-1301: Clinical Trial Results
  • Table 8.21 Therapy Profile: MDG108 (Medigene)
  • Table 8.22 MDG108: Clinical Trial Information
  • Table 8.23 MDG108: Clinical Trial Endpoints
  • Table 8.24 MDG108: Clinical Trial Results
  • Table 9.1 List of Partnerships and Collaborations, 2005-2022
  • Table 10.1 List of Funding and Investments, 2007-2022
  • Table 10.2 Funding and Investment Analysis: Summary of Investments
  • Table 11.1 Patent Analysis: Prominent CPC Symbols
  • Table 11.2 Patent Analysis: Most Popular CPC Symbols
  • Table 11.3 Patent Analysis: List of Top CPC Symbols
  • Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 12.1 Assessment Strategies for Different Manufacturing Processes
  • Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
  • Table 13.1 Price of Marketed Gene / Cell Therapies
  • Table 13.2 Price of Marketed Targeted Drugs
  • Table 13.3 TCR-based Therapies: Expert Opinions on Pricing
  • Table 13.4 TCR-based Therapies: Reimbursement Landscape
  • Table 14.1 TCR-based Therapies: List of Forecasted Molecules
  • Table 14.2 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore): Net Present Value (USD Million)
  • Table 14.3 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore): Value Creation Analysis (USD Million)
  • Table 14.4 GSK3377794 (GlaxoSmithKline): Net Present Value (USD Million)
  • Table 14.5 GSK3377794 (GlaxoSmithKline): Value Creation Analysis (USD Million)
  • Table 14.6 YT-E001 (China Immunotech): Net Present Value (USD Million)
  • Table 14.7 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
  • Table 14.8 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Net Present Value (USD Million)
  • Table 14.9 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
  • Table 14.10 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Net Present Value (USD Million)
  • Table 14.11 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Value Creation Analysis (USD Million)
  • Table 14.12 NTLA-5001 (Intellia Therapeutics): Net Present Value (USD Million)
  • Table 14.13 NTLA-5001 (Intellia Therapeutics): Value Creation Analysis (USD Million)
  • Table 14.14 TBI-1301 (Takara Bio): Net Present Value (USD Million)
  • Table 14.15 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
  • Table 14.16 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
  • Table 14.17 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
  • Table 14.18 FH-MCVA2TCR (TCRCure Biopharma): Net Present Value (USD Million)
  • Table 14.19 FH-MCVA2TCR (TCRCure Biopharma): Value Creation Analysis (USD Million)
  • Table 15.1 Kimmtrak®: Drug Overview
  • Table 16.1 Leading TCR-based Therapy Developers
  • Table 16.2 Adaptimmune Therapeutics: Company Profile
  • Table 16.3 Alaunos Therapeutics: Company Profile
  • Table 16.4 Bristol Myers Squibb: Company Profile
  • Table 16.5 Cellular Biomedicine Group: Company Profile
  • Table 16.6 Gilead Sciences: Company Profile
  • Table 16.7 GlaxoSmithKline: Company Profile
  • Table 16.8 Immatics: Company Profile
  • Table 16.9 Immunocore: Company Profile
  • Table 16.10 Lion TCR: Company Profile
  • Table 16.11 Takara Bio: Company Profile
  • Table 16.12 Zelluna Immunotherapy: Company Profile
  • Table 19.1 TCR-based Therapies: Distribution by Type of Developer
  • Table 19.2 TCR-based Therapies: Distribution by Phase of Development
  • Table 19.3 TCR-based Therapies: Distribution by Therapeutic Area
  • Table 19.4 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
  • Table 19.5 TCR-based Therapies: Distribution by Key Target Indications
  • Table 19.6 TCR-based Therapies: Distribution by Key Target Antigens
  • Table 19.7 TCR-based Therapies: Distribution by Source of T-Cells
  • Table 19.8 TCR-based Therapies: Distribution by Phase of Development and Source of T-Cells
  • Table 19.9 TCR-based Therapies: Distribution by Route of Administration
  • Table 19.10 TCR-based Therapies: Distribution by Dosing Frequency
  • Table 19.11 TCR-based Therapies: Distribution by Target Patient Segment
  • Table 19.12 TCR-based Therapies: Distribution by Type of Therapy
  • Table 19.13 Most Active Industry Players: Analysis by Number of TCR-based Therapies
  • Table 19.14 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
  • Table 19.15 TCR-based Therapy Developers: Distribution by Year of Establishment
  • Table 19.16 TCR-based Therapy Developers: Distribution by Company Size
  • Table 19.17 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
  • Table 19.18 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
  • Table 19.19 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2013-2022
  • Table 19.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
  • Table 19.21 Clinical Trial Analysis: Distribution by Trial Status
  • Table 19.22 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
  • Table 19.23 Clinical Trial Analysis: Distribution of Trials by Trial Phase
  • Table 19.24 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 19.25 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Table 19.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 19.27 Clinical Trial Analysis: Distribution by Study Design
  • Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
  • Table 19.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 19.30 Clinical Trial Analysis: Distribution of Trials by Geography
  • Table 19.31 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
  • Table 19.32 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
  • Table 19.33 Clinical Trial Analysis: Distribution of Enrolled Patient Population by

Geography

  • Table 19.34 KOL Analysis: Distribution by Type of Organization
  • Table 19.35 KOL Analysis: Distribution by Affiliated Organization
  • Table 19.36 KOL Analysis: Distribution by Qualification
  • Table 19.37 KOL Analysis: Distribution by Geography
  • Table 19.38 Most Prominent KOLs: Distribution by RA Score
  • Table 19.39 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Table 19.40 Kimmtrak®: Estimated Sales Revenues
  • Table 19.41 GSK3377794: Estimated Sales Revenues
  • Table 19.42 ADP-A2M4: Estimated Sales Revenues
  • Table 19.43 JTCR016: Estimated Sales Revenues
  • Table 19.44 TBI-1301: Estimated Sales Revenues
  • Table 19.45 MDG1011: Estimated Sales Revenues
  • Table 19.46 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
  • Table 19.47 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 19.48 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
  • Table 19.49 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 19.50 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
  • Table 19.51 Most Popular Products: Distribution by Number of Partnerships
  • Table 19.52 Most Active Industry Players: Distribution by Number of Partnerships
  • Table 19.53 Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Table 19.54 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
  • Table 19.55 Partnerships and Collaborations: Distribution of International and Local Deals
  • Table 19.56 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
  • Table 19.57 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
  • Table 19.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Table 19.59 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Table 19.60 Funding and Investment Analysis: Distribution by Type of Investor
  • Table 19.61 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
  • Table 19.62 Most Active Players: Distribution by Number of Instances
  • Table 19.63 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 19.64 Funding and Investment Analysis: Distribution of Amount Invested by Geography
  • Table 19.65 Patent Analysis: Distribution by Type of Patent
  • Table 19.66 Patent Analysis: Cumulative Distribution by Patent Publication Year
  • Table 19.67 Patent Analysis: Cumulative Distribution Patent Application Year
  • Table 19.68 Patent Analysis: Cumulative Distribution by Annual Granted Patents
  • Table 19.69 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
  • Table 19.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
  • Table 19.71 Patent Analysis: Distribution by Geography
  • Table 19.72 Patent Analysis: Distribution by Type of Player
  • Table 19.73 Patent Analysis: Distribution by CPC Symbols
  • Table 19.74 Leading Industry Players: Distribution by Number of Patents
  • Table 19.75 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 19.76 Leading Patent Assignees: Distribution by Number of Patents
  • Table 19.77 Patent Analysis: Distribution by Patent Age
  • Table 19.78 TCR-based Therapies: Patent Valuation Analysis

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Clinical Trial Analysis
  • Figure 2.3 Executive Summary: Partnerships and Collaborations
  • Figure 2.4 Executive Summary: Funding and Investment Analysis
  • Figure 2.5 Executive Summary: Patent Analysis
  • Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Pillars of Cancer Therapy
  • Figure 3.2 Differences between Active and Passive Immunotherapies
  • Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
  • Figure 3.4 Strategies Employed for the Redirection of T-Cells
  • Figure 3.5 T-Cell Manufacturing: General Procedure
  • Figure 3.6 TCR-based Therapies: Development Process
  • Figure 4.1 TCR-based Therapies: Distribution by Type of Developer
  • Figure 4.2 TCR-based Therapies: Distribution by Phase of Development
  • Figure 4.3 TCR-based Therapies: Distribution by Therapeutic Area
  • Figure 4.4 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
  • Figure 4.5 TCR-based Therapies: Distribution by Key Target Indications
  • Figure 4.6 TCR-based Therapies: Distribution by Key Target Antigens
  • Figure 4.7 TCR-based Therapies: Distribution by Source of T-Cells
  • Figure 4.8 TCR-based Therapies: Distribution by Phase of Development and Source of T-Cells
  • Figure 4.9 TCR-based Therapies: Distribution by Route of Administration
  • Figure 4.10 TCR-based Therapies: Distribution by Dosing Frequency
  • Figure 4.11 TCR-based Therapies: Distribution by Target Patient Segment
  • Figure 4.12 TCR-based Therapies: Distribution by Type of Therapy
  • Figure 4.13 Most Active Industry Players: Distribution by Number of TCR-based Therapies
  • Figure 4.14 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
  • Figure 4.15 TCR-based Therapy Developers: Distribution by Year of Establishment
  • Figure 4.16 TCR-based Therapy Developers: Distribution by Company Size
  • Figure 4.17 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.18 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
  • Figure 5.1 TCR-based Therapies: Popular Targets in Hematological Malignancies
  • Figure 5.2 TCR-based Therapies: Popular Targets in Solid Tumors
  • Figure 6.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 6.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2013-2022
  • Figure 6.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
  • Figure 6.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
  • Figure 6.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
  • Figure 6.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 6.8 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Figure 6.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 6.10 Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.11 Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 6.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 6.13 Word Cloud Analysis: Emerging Focus Areas
  • Figure 6.14 Clinical Trial Analysis: Distribution of Trials by Geography
  • Figure 6.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
  • Figure 6.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
  • Figure 6.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by

Geography

  • Figure 7.1 KOL Analysis: Distribution by Type of Organization
  • Figure 7.2 KOL Analysis: Distribution by Affiliated Organization
  • Figure 7.3 KOL Analysis: Distribution by Qualification
  • Figure 7.4 KOL Analysis: Distribution by Geography
  • Figure 7.5 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
  • Figure 7.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
  • Figure 7.7 Most Prominent KOLs: Distribution by RA Score
  • Figure 7.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Figure 7.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
  • Figure 8.1 Kimmtrak®: Estimated Sales Revenues
  • Figure 8.2 GSK3377794: Estimated Sales Revenues
  • Figure 8.3 ADP-A2M4: Estimated Sales Revenues
  • Figure 8.4 JTCR016: Estimated Sales Revenues
  • Figure 8.5 TBI-1301: Estimated Sales Revenues
  • Figure 8.6 MDG1011: Estimated Sales Revenues
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
  • Figure 9.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015-2022
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
  • Figure 9.7 Most Popular Products: Distribution by Number of Partnerships
  • Figure 9.8 Most Active Industry Players: Distribution by Number of Partnerships
  • Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 9.11 Partnerships and Collaborations: International and Local Deals
  • Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2018-2022
  • Figure 10.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2018-2022 (USD Million)
  • Figure 10.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Figure 10.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 10.5 Funding and Investment Analysis: Distribution by Type of Investor
  • Figure 10.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
  • Figure 10.7 Most Active Players: Distribution by Number of Instances
  • Figure 10.8 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
  • Figure 11.1 Patent Analysis: Distribution by Type of Patent
  • Figure 11.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
  • Figure 11.3 Patent Analysis: Cumulative Distribution by Patent Application Year
  • Figure 11.4 Patent Analysis: Cumulative Year-wise Distribution of Granted Patents
  • Figure 11.5 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
  • Figure 11.6 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents
  • Figure 11.7 Patent Analysis: Distribution by Geography
  • Figure 11.8 Patent Analysis: Distribution by Type of Player
  • Figure 11.9 Patent Analysis: Distribution by CPC Symbols
  • Figure 11.10 Patent Analysis: Key Focus Area
  • Figure 11.11 Leading Industry Players: Distribution by Number of Patents
  • Figure 11.12 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 11.13 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 11.14 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 11.15 Patent Analysis: Distribution by Patent Age
  • Figure 11.14 TCR-based Cell Therapies: Patent Valuation Analysis
  • Figure 12.1 Steps for Manufacturing Cell Therapies
  • Figure 12.2 Centralized Manufacturing: Process Model
  • Figure 12.3 Decentralized Manufacturing: Process Model
  • Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 12.5 Cell Therapy: Challenges and Drivers
  • Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
  • Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
  • Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
  • Figure 13.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
  • Figure 14.1 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
  • Figure 14.2 TCR-based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
  • Figure 14.3 TCR-based Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
  • Figure 14.4 TCR-based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
  • Figure 14.5 TCR-based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
  • Figure 14.6 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast, till 2035 (USD Million)
  • Figure 14.7 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
  • Figure 14.8 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
  • Figure 14.9 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
  • Figure 14.10 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
  • Figure 14.11 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
  • Figure 14.12 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
  • Figure 14.13 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2035 (USD Million)
  • Figure 15.1 Channels Used for Promotional Campaigns
  • Figure 15.2 Product Website Analysis: Kimmtrak®, Messages for Healthcare Professional
  • Figure 15.3 Product Website Analysis: Kimmtrak®, Messages for Patients
  • Figure 15.4 Product Website Analysis: Kimmtrak®, Kimmtrak Connect
  • Figure 17.1 Concluding Remarks: Market Landscape
  • Figure 17.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 17.3 Concluding Remarks: Key Opinion Leaders
  • Figure 17.4 Concluding Remarks: Partnerships & Collaborations
  • Figure 17.5 Concluding Remarks: Funding and Investment Analysis
  • Figure 17.6 Concluding Remarks: Patent Analysis
  • Figure 17.7 Concluding Remarks: Market Forecast
目次
Product Code: RA100404

INTRODUCTION

Modified T-cell receptor (TCR)-based therapy is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Their tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host with negligible treatment-related side effects. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TCR-based therapy market is likely to witness significant growth in the foreseen future.

SCOPE OF THE REPORT

The "Global TCR-based Therapy Market (2nd Edition), 2022-2035: Distribution by Target Indication (Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, and Merkel Cell Cancer), Target Antigen (NY-ESO-1, EBV, gp100, and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current market landscape and future potential of TCR-based therapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. The report answers many key questions related to this domain:

Need for TCR-based Therapies for the Treatment of Various Types of Cancer

Modified T-cell receptor (TCR)-based therapies, an upcoming class of cell-based interventions, is a promising therapeutic modality. Similar to other T-cell based interventions (such as CAR-T cells and TILs), TCR-based therapies are designed to target the underlying causes (or primary mediators) of a clinical condition. Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate. , Although TCR-based immunotherapies are still considered an experimental approach, several clinical studies demonstrate the efficacy and therapeutic superiority of TCR cell products.

Current Market Landscape of TCR-based Therapies

Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders. It is worth highlighting that, in January 2022, the FDA approved the first TCR-based therapy, Kimmtrak® (Immunocore), for the treatment of adult patients with unresectable or metastatic uveal melanoma. More than 90% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature. Further, NY-ESO-1 and MAGE emerged as the most popular target antigens in this domain.

Rising Interest in TCR-based Therapies

The growing interest in this field is reflected in the notable increase in partnerships inked (close to 140 deals inked in the past decade; CAGR 23%) by several industry players and academic / research institutes. Additionally, various investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion across 140 instances, since 2007. Further, in the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR-based therapies. Mostly driven by the need for effective treatment options for cancer, the TCR-based therapy pipeline is expected to steadily grow over the coming years. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives.

Market Size of the TCR-based Therapy Market

With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma. Additionally, more than 80% of the market is anticipated to be captured by players based in Europe and Asia-Pacific in 2035. Overall, we are led to believe that the global TCR-based therapy market is poised to witness significant growth in the foreseen future.

Who are the Key Players in the TCR-based Therapy Market

Examples of key players engaged in this domain (which have also been captured in this report) include Adaptimmune Therapeutics, Alaunos Therapeutics, blubird bio, Bristol Myers Squibb, Cellular Biomedicine Group, China Immunotech, Gilead Sciences, GlaxoSmithKline, Immatics

Immunocore, Intellia Therapeutics, Lion TCR, Takara Bio, TCRCure Biopharma, and Zelluna Immunotherapy.

The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of global TCR-based therapies market and its likely evolution in the mid-long term.
  • A general overview of TCR-based therapies in comparison to conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in development of TCR-based therapies
  • A detailed assessment of the overall market landscape of TCR-based therapies, based on several relevant parameters, such as type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, and preclinical), therapeutic area (hematological cancer, solid tumor, and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma, cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, nasopharyngeal carcinoma, and others), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso, HLA, and others), source of T-cells (autologous / allogeneic), route of administration (intravenous and intratumoral), dosing frequency (single dose, multiple dose, and split dose), target patient segment (children, adults, and elderly patients), type of therapy (monotherapy and combination therapy) and most active players (in terms of number of TCR-based therapies). Further, the chapter also provides developer landscape of industry and non-industry players engaged in this domain.
  • A detailed analysis of popular target antigens, based on the number of TCR-based therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
  • An analysis of completed, ongoing, and planned clinical studies related to TCR-based therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, target patient segment, type of sponsor / collaborator, most active players (in terms of number of registered trials), key focus areas and geography.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to TCR-based therapies, considering them to be KOLs, who are actively involved in R&D of TCR-based therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.
  • Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), a clinical development plan, and clinical trial results.
  • A detailed analysis of recent partnerships inked between several stakeholders engaged in this domain, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures, and others.
  • An analysis of the funding and investments that have been made into companies having proprietary TCR-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
  • An in-depth analysis of patents related to TCR-based therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted, patent applications, and search reports), patent publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus area, type of player, leading player (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • A n elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a TCR-based therapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that are being implemented by the developers of the approved TCR-based therapy (Kimmtrak®).
  • Elaborate profiles of the leading players in the domain of TCR-based therapies. Each company profile includes an overview of the developer and a brief description of the product portfolio specific to TCR-based therapies, the technology portfolio (if available), recent developments related to TCR-based therapies, and the manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the current opportunity and the future growth potential of TCR-based therapies over the coming decade. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of TCR-based therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TCR-based therapies market, wherein both the current and upcoming opportunity is segmented across target indication (nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and merkel cell cancer), target antigen (NY-ESO-1, EBV, gp100 and others), key players and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Former Chief Operating Officer, TxCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What is the growth rate of TCR-based therapy market?

Answer: The global TCR-based therapies market is expected to grow at a compound annual growth rate of 51% from 2022-2035.

Question 2: Which region has the highest growth rate in the TCR-based Therapies market?

Answer: Asia Pacific is growing at the highest CAGR, over the period 2022- 2035.

Question 3: How many players are developing TCR-based Therapies?

Answer: More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders.

Question 4: Which target indication covers the largest TCR-based therapy market share?

Answer: Multiple myeloma, presently, captures the maximum share (43%) of TCR-based therapy market in 2022. This share is likely to decrease in the foreseen future as several promising leads are anticipated to be commercially launched over the coming decade.

Question 5: What is the partnership and collaboration trend in the TCR-based therapy domain?

Answer: Currently, R&D agreements, licensing agreements, and product development and commercialization agreements are the common type of partnerships inked by developers involved in the TCR-based therapy domain.

Question 6: What is the current IP landscape of TCR-based therapies market?

Answer: Close to 76% of the filed patents were patent applications, while around 24% were granted patents and search reports. Of the total granted applications, close to 78% were filed in the US.

CHAPTER OUTLINES

Chapter 1: is a preface providing an introduction to the full report, TCR-based therapy market (2nd Edition), 2022-2035.

Chapter 2: provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the TCR-based therapy market in the short to mid-term and long term.

Chapter 3: provides a general overview of TCR-based therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in development of TCR-based therapies.

Chapter 4: includes detailed assessment of the current market landscape of more than 190 TCR-based therapies that are currently approved or are in different stages of the development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry / non-industry), phase of development (approved, phase II, phase I / II, phase I, and preclinical), therapeutic area (hematological cancer, solid tumor, and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma, cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, nasopharyngeal carcinoma, and others), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso, HLA, and others), source of T-cells (autologous / allogeneic), route of administration (intravenous and intratumoral), dose frequency (single dose, multiple dose, and split dose), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in development of TCR-based therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized, and large) and location of headquarters (North America, Europe, and Asia Pacific).

Chapter 5: presents a comprehensive target antigen analysis, highlighting the most popular target antigens related to hematological malignancies and solid tumors, based on the number of TCR-based therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.

Chapter 6: presents a detailed analysis of completed, ongoing, and planned clinical studies related to TCR-based therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players (in terms of number of registered trials), and geography.

Chapter 7: presents an analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to TCR-based therapies, considering them to be KOLs, who are actively involved in R&D of TCR-based therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.

Chapter 8: provides detailed profiles of marketed and mid to late stage TCR-based therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 9: features an analysis of the recent partnerships inked between several stakeholders engaged in this domain, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures, and others, companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 10: provides details on the various funding and investments that have been made into companies having proprietary TCR-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing. It includes a detailed analysis of the funding instances that have taken place in the period between 2005 to 2022, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 11: provides an in-depth analysis of patents related to TCR-based therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted, patent applications, and search reports), patent publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus area, type of player, leading player (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents.

Chapter 12: provides case study on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. Additionally, it includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 13: highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their TCR-based therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for TCR-based therapies.

Chapter 14: features an elaborate discussion on the future commercial opportunity offered by TCR-based therapies. It provides a comprehensive market forecast analysis for TCR-based products that are approved or are in phase I/II and phase II of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation, based on target indication (nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and merkel cell cancer), target antigen (NY-ESO-1, EBV, gp100 and others), key players, and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World).

Chapter 15: highlights the key promotional strategies that are being implemented by the developers of the approved TCR-based therapy (Kimmtrak®). The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings, and informative downloadable content.

Chapter 16: includes brief company profiles of the leading players in the domain of TCR-based therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to TCR-based therapies, technology portfolio (if available), recent developments related to TCR-based therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 17: is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18: is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), and Miguel Forte (Former Chief Operating Officer, TxCell).

Chapter 19: is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20: is an appendix, which contains a list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Chapter Overview
  • 1.2. Market Segmentations
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Pillars of Cancer Therapy
  • 3.3. Overview of Immunotherapies
  • 3.4. Fundamentals of Cancer Immunotherapy
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
      • 3.5.1.1. Active Immunotherapy
      • 3.5.1.2. Passive Immunotherapy
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
      • 3.5.3.1. Activation and Suppression Immunotherapy
    • 3.5.4. By Product Class
      • 3.5.4.1. Monoclonal Antibodies
      • 3.5.4.2. Bispecific Antibodies
      • 3.5.4.3. Cytokines
      • 3.5.4.4. Oncolytic Virus Therapy
      • 3.5.4.5. Therapeutic Cancer Vaccines
      • 3.5.4.6. Cell-based Therapies
  • 3.6. T-Cell Immunotherapies
    • 3.6.1. Historical Evolution
    • 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
    • 3.6.3. Strategies Employed for the Redirection of T-Cells
    • 3.6.4. Manufacturing of Engineered T-Cells
    • 3.6.5. T-Cell Transduction and Transfection Methods
      • 3.6.5.1. Retroviral Vectors
      • 3.6.5.2. Lentiviral Vectors
      • 3.6.5.3. Non-viral Transfection Methods
  • 3.7. T-Cell Receptor (TCR)-based Cell Therapy
    • 3.7.1. Development History
    • 3.7.2. Anatomical Layout of TCR
    • 3.7.3. Development of TCR Therapy
    • 3.7.4. Differences between CAR-T and TCR-based Therapies
  • 3.8. Concluding Remarks

4. TCR-BASED THERAPIES: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. TCR-based Therapies: Overall Market Landscape
    • 4.2.1. Analysis by Type of Developer
    • 4.2.2. Analysis by Phase of Development
    • 4.2.3. Analysis by Therapeutic Area
    • 4.2.4. Analysis by Phase of Development and Therapeutic Area
    • 4.2.5. Analysis by Key Target Indication
    • 4.2.6. Analysis by Key Target Antigen
    • 4.2.7. Analysis by Source of T-Cells
    • 4.2.8. Analysis by Route of Administration
    • 4.2.9. Analysis by Phase of Development and Route of Administration
    • 4.2.10. Analysis by Dosing Frequency
    • 4.2.11. Analysis by Target Patient Segment
    • 4.2.12. Analysis by Type of Therapy
    • 4.2.13. Analysis by Phase of Development and Type of Therapy
    • 4.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
    • 4.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies
  • 4.3. TCR-based Therapies: Overall Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters

5. POPULAR TARGET ANTIGEN ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Competitive Analysis: Popular Target Antigens of TCR-based Therapies
    • 5.2.1. Popular Targets Related to Hematological Malignancies
    • 5.2.2. Popular Targets Related to Solid Tumors

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. TCR-based Therapies: Clinical Trial Analysis
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 6.3.3. Analysis by Trial Status
    • 6.3.4. Analysis by Trial Registration Year and Trial Status
    • 6.3.5. Analysis by Trial Phase
    • 6.3.6. Analysis of Enrolled Patient Population by Trial Phase
    • 6.3.7. Analysis by Target Patient Segment
    • 6.3.8. Analysis by Type of Sponsor / Collaborator
    • 6.3.9. Analysis by Study Design
    • 6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
    • 6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
    • 6.3.12. Word Cloud Representation Analysis: Emerging Focus Areas
    • 6.3.13. Analysis of Clinical Trials by Geography
    • 6.3.14. Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS

  • 7.1. Chapter Overview
  • 7.2. Assumptions and Key Parameters
  • 7.3. Methodology
  • 7.4. TCR-based Therapies: Key Opinion Leaders
    • 7.4.1. Analysis by Type of Organization
    • 7.4.2. Analysis by Affiliated Organization
    • 7.4.3. Analysis by Qualification
    • 7.4.4. Analysis by Geographical Location of KOLs
    • 7.4.5. KOL Activeness versus KOL Strength
    • 7.4.6. Most Prominent KOLs: Analysis by RA score
    • 7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. TCR-BASED THERAPY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Kimmtrak® / IMCgp100 / Tebentafusp (Immunocore)
    • 8.2.1. Therapy Overview
    • 8.2.2. Clinical Trial Information
    • 8.2.3. Clinical Trial Endpoints
    • 8.2.4. Clinical Trial Results
    • 8.2.5. Estimated Sales Revenues
  • 8.3. GSK3377794 / NY-ESO-1C259 T-cells / Letetresgene Autoleucel (GlaxoSmithKline)
    • 8.3.1. Therapy Overview
    • 8.3.2. Clinical Trial Information
    • 8.3.3. Clinical Trial Endpoints
    • 8.3.4. Clinical Trial Results
    • 8.3.5. Estimated Sales Revenues
  • 8.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
    • 8.4.1. Therapy Overview
    • 8.4.2. Clinical Trial Information
    • 8.4.3. Clinical Trial Endpoints
    • 8.4.4. Clinical Trial Results
    • 8.4.5. Estimated Sales Revenues
  • 8.5. JTCR016 (Juno Therapeutics)
    • 8.5.1. Therapy Overview
    • 8.5.2. Clinical Trial Information
    • 8.5.3. Clinical Trial Endpoints
  • 8.6. TBI-1301 (Takara Bio)
    • 8.6.1. Therapy Overview
    • 8.6.2. Clinical Trial Information
    • 8.6.3. Clinical Trial Endpoints
    • 8.6.4. Clinical Trial Results
    • 8.6.5. Estimated Sales Revenues
  • 8.7. MDG1011 (Medigene)
    • 8.7.1. Therapy Overview
    • 8.7.2. Clinical Trial Information
    • 8.7.3. Clinical Trial Endpoints
    • 8.7.4. Clinical Trial Results

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. TCR-based Therapies: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year of Partnership and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Most Popular Products: Analysis by Number of Partnerships
    • 9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
    • 9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
    • 9.3.8. Analysis by Geography
      • 9.3.8.1. Intercontinental and Intracontinental Deals
      • 9.3.8.2. International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Types of Funding
  • 10.3. TCR-based Therapies: Funding and Investment Analysis
    • 10.3.1. Analysis of Instances by Year
    • 10.3.2. Analysis of Amount Invested by Year
    • 10.3.3. Analysis by Type of Funding
    • 10.3.4. Analysis by Type of Investor
    • 10.3.5. Most Active Players: Analysis by Number of Instances
    • 10.3.6. Most Active Investors: Analysis by Amount Invested
    • 10.3.7. Analysis of Amount Invested by Geography
    • 10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. TCR-based Therapies: Patent Analysis
    • 11.3.1. Analysis by Patent Publication Year
    • 11.3.2. Analysis By Patent Application Year
    • 11.3.3. Analysis by Geography
    • 11.3.4. Analysis by Type of Player
    • 11.3.5. Analysis by CPC Symbols
    • 11.3.6. Analysis by Key Focus Area
    • 11.3.7. Leading Player: Analysis by Number of Patents
    • 11.3.8. TCR-based Therapies: Patent Benchmarking
    • 11.3.9. Analysis By Patent Characteristics
    • 11.3.10. TCR-based Cell Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING

  • 12.1. Chapter Overview
  • 12.2. Overview of Cell Therapy Manufacturing
  • 12.3. Cell Therapy Manufacturing Models
    • 12.3.1. Centralized Manufacturing Model
    • 12.3.2. Decentralized Manufacturing Model
  • 12.4. Scalability of Cell Therapy Manufacturing Processes
    • 12.4.1. Scale-Up
    • 12.4.2. Scale-Out
  • 12.5. Types of Cell Therapy Manufacturers
  • 12.6. Key Challenges Related to Manufacturing of Cell Therapies
  • 12.7. Important Factors for Cell Therapy Manufacturing
    • 12.7.1. Characterization
    • 12.7.2. Cost of Goods
  • 12.8. Automation of Cell Therapy Manufacturing Processes
  • 12.9. Cell Therapy Manufacturing Supply Chain
  • 12.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
  • 12.11. Regulatory Landscape
  • 12.12. Future Perspectives

13. COST PRICE ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Factors Contributing to the High Price of Cell / Gene Therapies
  • 13.3. Pricing Models for T-Cell Immunotherapies
    • 13.3.1. Based on Associated Costs
    • 13.3.2. Based on Availability of Competing Products
    • 13.3.3. Based on Patient Segment
    • 13.3.4. Based on Opinions of Industry Experts
  • 13.4. Reimbursement related Considerations for T-cell Immunotherapies
    • 13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Scope and Limitations
  • 14.3. Key Assumptions and Forecast Methodology
  • 14.4. Global TCR-based Therapies Market, 2022-2035
    • 14.4.1. TCR-based Therapies Market: Analysis by Target Indication
    • 14.4.2. TCR-based Therapies Market: Analysis by Target Antigen
    • 14.4.3. TCR-based Therapies Market: Analysis by Key Players
    • 14.4.4. TCR-based Therapies Market: Distribution by Geography
    • 14.4.5. Product Wise Sales Forecast
      • 14.4.5.1. Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore)
        • 14.4.5.1.1. Sales Forecast (USD Million)
        • 14.4.5.1.2. Net Present Value (USD Million)
        • 14.4.5.1.3. Value Creation Analysis
      • 14.4.5.2. GSK3377794 (GlaxoSmithKline)
        • 14.4.5.2.1. Sales Forecast (USD Million)
        • 14.4.5.2.2. Net Present Value (USD Million)
        • 14.4.5.2.3. Value Creation Analysis
      • 14.4.5.3. YT-E001 (China Immunotech)
        • 14.4.5.3.1. Sales Forecast (USD Million)
        • 14.4.5.3.2. Net Present Value (USD Million)
        • 14.4.5.3.3. Value Creation Analysis
      • 14.4.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
        • 14.4.5.4.1. Sales Forecast (USD Million)
        • 14.4.5.4.2. Net Present Value (USD Million)
        • 14.4.5.4.3. Value Creation Analysis
      • 14.4.5.5. EBV-specific TCR-T cell with Anti-PD1 Aauto-secreted Element (TCRCure Biopharma)
        • 14.4.5.5.1. Sales Forecast (USD Million)
        • 14.4.5.5.2. Net Present Value (USD Million)
        • 14.4.5.5.3. Value Creation Analysis
      • 14.4.5.6. NTLA-5001 (Intellia Therapeutics)
        • 14.4.5.6.1. Sales Forecast (USD Million)
        • 14.4.5.6.2. Net Present Value (USD Million)
        • 14.4.5.6.3. Value Creation Analysis
      • 14.4.5.7. TBI-1301 (Takara Bio)
        • 14.4.5.7.1. Sales Forecast (USD Million)
        • 14.4.5.7.2. Net Present Value (USD Million)
        • 14.4.5.7.3. Value Creation Analysis
      • 14.4.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
        • 14.4.5.8.1. Sales Forecast (USD Million)
        • 14.4.5.8.2. Net Present Value (USD Million)
        • 14.4.5.8.3. Value Creation Analysis
      • 14.4.5.9. FH-MCVA2TCR (TCRCure Biopharma)
        • 14.4.5.9.1. Sales Forecast (USD Million)
        • 14.4.5.9.2. Net Present Value (USD Million)
        • 14.4.5.9.3. Value Creation Analysis

15. PROMOTIONAL ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Channels Used for Promotional Campaigns
  • 15.3. Kimmtrak: Promotional Analysis
    • 15.3.1. Drug Overview
    • 15.3.2. Product Website Analysis
      • 15.3.2.1. Message for Healthcare Professionals
      • 15.3.2.2. Message for Patients
      • 15.3.2.3. Informative Downloads
    • 15.3.3. Patient Support Services

16. COMPANY PROFILES

  • 16.1. Chapter Overview
  • 16.2. Adaptimmune Therapeutics
  • 16.3. Alaunos Therapeutics
  • 16.4. Company Profiles
  • 16.5. Bristol Myers Squibb
  • 16.6. Cellular Biomedicine Group
  • 16.7. Gilead Sciences
  • 16.8. Cellular Biomedicine Group
  • 16.9. GlaxoSmithKline
  • 16.10. Immatics
  • 16.11. Immunocore
  • 16.12. Lion TCR
  • 16.13. Takara Bio
  • 16.14. Zelluna immunotherapy

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

  • 18.1. Chapter Overview
  • 18.2. Celyad
    • 18.2.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
  • 18.3. Kite Pharma
    • 18.3.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
  • 18.4. Lion TCR
    • 18.4.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
  • 18.5. TxCell
    • 18.5.1. Interview Transcript: Miguel Forte, Chief Operating Officer

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS